Recent study reports CAGR of 9.7% in precision medicine space. Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies. One of POAI’s primary projects is building multi-omic predictive models of tumor drug response A recent study of the global precision medicine market indicates a bright future for the industry, especially … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Industry Leader in Growing Precision Medicine Market”
Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://nnw.fm/38wOl). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books”
Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Shareholder Letter Provides Company Update, Status of Subsidiaries”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (http://nnw.fm/XeQG6). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!”
Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments”
POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines”
POAI subsidiary Helomics exec discusses the company’s quest to fight cancer Helomics tapping into the fast growing, billion-dollar AI in drug discovery market Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling for two decades Helomics harnesses rich historic tumor data with the power of AI to test living tumor tissues Predictive … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment”
